Literature DB >> 34017133

XCR1+ type 1 conventional dendritic cells drive liver pathology in non-alcoholic steatohepatitis.

Assaf Weiner1, Ziv Ben-Ari2,3, Mathias Heikenwälder4, Eran Elinav5,6, Ido Amit7, Aleksandra Deczkowska8,9, Eyal David1, Pierluigi Ramadori10, Dominik Pfister10, Michal Safran2, Baoguo Li1, Amir Giladi1, Diego Adhemar Jaitin1, Oren Barboy1, Merav Cohen1,11, Ido Yofe1, Chamutal Gur1,12, Shir Shlomi-Loubaton1, Sandrine Henri13, Yousuf Suhail14, Mengjie Qiu14, Shing Kam10, Hila Hermon15, Eylon Lahat16, Gil Ben Yakov2, Oranit Cohen-Ezra2, Yana Davidov2, Mariya Likhter2, David Goitein15,3, Susanne Roth14, Achim Weber17, Bernard Malissen13,18.   

Abstract

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are prevalent liver conditions that underlie the development of life-threatening cirrhosis, liver failure and liver cancer. Chronic necro-inflammation is a critical factor in development of NASH, yet the cellular and molecular mechanisms of immune dysregulation in this disease are poorly understood. Here, using single-cell transcriptomic analysis, we comprehensively profiled the immune composition of the mouse liver during NASH. We identified a significant pathology-associated increase in hepatic conventional dendritic cells (cDCs) and further defined their source as NASH-induced boost in cycling of cDC progenitors in the bone marrow. Analysis of blood and liver from patients on the NAFLD/NASH spectrum showed that type 1 cDCs (cDC1) were more abundant and activated in disease. Sequencing of physically interacting cDC-T cell pairs from liver-draining lymph nodes revealed that cDCs in NASH promote inflammatory T cell reprogramming, previously associated with NASH worsening. Finally, depletion of cDC1 in XCR1DTA mice or using anti-XCL1-blocking antibody attenuated liver pathology in NASH mouse models. Overall, our study provides a comprehensive characterization of cDC biology in NASH and identifies XCR1+ cDC1 as an important driver of liver pathology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34017133     DOI: 10.1038/s41591-021-01344-3

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  61 in total

Review 1.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases.

Authors:  Naga Chalasani; Zobair Younossi; Joel E Lavine; Michael Charlton; Kenneth Cusi; Mary Rinella; Stephen A Harrison; Elizabeth M Brunt; Arun J Sanyal
Journal:  Hepatology       Date:  2017-09-29       Impact factor: 17.425

Review 2.  The Liver at the Nexus of Host-Microbial Interactions.

Authors:  Andrew J Macpherson; Mathias Heikenwalder; Stephanie C Ganal-Vonarburg
Journal:  Cell Host Microbe       Date:  2016-11-09       Impact factor: 21.023

Review 3.  Liver macrophages in tissue homeostasis and disease.

Authors:  Oliver Krenkel; Frank Tacke
Journal:  Nat Rev Immunol       Date:  2017-03-20       Impact factor: 53.106

4.  Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes.

Authors:  Monika Julia Wolf; Arlind Adili; Kira Piotrowitz; Zeinab Abdullah; Yannick Boege; Kerstin Stemmer; Marc Ringelhan; Nicole Simonavicius; Michèle Egger; Dirk Wohlleber; Anna Lorentzen; Claudia Einer; Sabine Schulz; Thomas Clavel; Ulrike Protzer; Christoph Thiele; Hans Zischka; Holger Moch; Matthias Tschöp; Alexei V Tumanov; Dirk Haller; Kristian Unger; Michael Karin; Manfred Kopf; Percy Knolle; Achim Weber; Mathias Heikenwalder
Journal:  Cancer Cell       Date:  2014-10-13       Impact factor: 31.743

Review 5.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis.

Authors:  Anna M Diehl; Christopher Day
Journal:  N Engl J Med       Date:  2017-11-23       Impact factor: 91.245

6.  As I see it. Research with patients requires commitment, savvy.

Authors:  M Walker
Journal:  Am Nurse       Date:  1983 Jul-Aug

Review 7.  Nonalcoholic fatty liver disease.

Authors:  Elizabeth M Brunt; Vincent W-S Wong; Valerio Nobili; Christopher P Day; Silvia Sookoian; Jacquelyn J Maher; Elisabetta Bugianesi; Claude B Sirlin; Brent A Neuschwander-Tetri; Mary E Rinella
Journal:  Nat Rev Dis Primers       Date:  2015-12-17       Impact factor: 52.329

8.  CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity.

Authors:  Satoshi Nishimura; Ichiro Manabe; Mika Nagasaki; Koji Eto; Hiroshi Yamashita; Mitsuru Ohsugi; Makoto Otsu; Kazuo Hara; Kohjiro Ueki; Seiryo Sugiura; Kotaro Yoshimura; Takashi Kadowaki; Ryozo Nagai
Journal:  Nat Med       Date:  2009-07-26       Impact factor: 53.440

Review 9.  From NASH to HCC: current concepts and future challenges.

Authors:  Quentin M Anstee; Helen L Reeves; Elena Kotsiliti; Olivier Govaere; Mathias Heikenwalder
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-07       Impact factor: 46.802

10.  Hepatic Natural Killer T-cell and CD8+ T-cell Signatures in Mice with Nonalcoholic Steatohepatitis.

Authors:  Jashdeep Bhattacharjee; Michelle Kirby; Samir Softic; Lili Miles; Rosa-Maria Salazar-Gonzalez; Pranav Shivakumar; Rohit Kohli
Journal:  Hepatol Commun       Date:  2017-05-16
View more
  23 in total

1.  Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH).

Authors:  Z Wang; Z Zhao; Y Xia; Z Cai; C Wang; Y Shen; R Liu; H Qin; J Jia; G Yuan
Journal:  J Endocrinol Invest       Date:  2022-02-28       Impact factor: 4.256

Review 2.  Non-alcoholic fatty liver disease: the interplay between metabolism, microbes and immunity.

Authors:  Herbert Tilg; Timon E Adolph; Michael Dudek; Percy Knolle
Journal:  Nat Metab       Date:  2021-12-20

3.  Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease.

Authors:  Naoto Fujiwara; Naoto Kubota; Emilie Crouchet; Bhuvaneswari Koneru; Cesia A Marquez; Arun K Jajoriya; Gayatri Panda; Tongqi Qian; Shijia Zhu; Nicolas Goossens; Xiaochen Wang; Shuang Liang; Zhenyu Zhong; Sara Lewis; Bachir Taouli; Myron E Schwartz; Maria Isabel Fiel; Amit G Singal; Jorge A Marrero; Austin J Fobar; Neehar D Parikh; Indu Raman; Quan-Zhen Li; Masataka Taguri; Atsushi Ono; Hiroshi Aikata; Takashi Nakahara; Hayato Nakagawa; Yuki Matsushita; Ryosuke Tateishi; Kazuhiko Koike; Masahiro Kobayashi; Takaaki Higashi; Shigeki Nakagawa; Yo-Ichi Yamashita; Toru Beppu; Hideo Baba; Hiromitsu Kumada; Kazuaki Chayama; Thomas F Baumert; Yujin Hoshida
Journal:  Sci Transl Med       Date:  2022-06-22       Impact factor: 19.319

4.  Platelets control liver tumor growth through P2Y12-dependent CD40L release in NAFLD.

Authors:  Chi Ma; Qiong Fu; Laurence P Diggs; John C McVey; Justin McCallen; Simon Wabitsch; Benjamin Ruf; Zachary Brown; Bernd Heinrich; Qianfei Zhang; Umberto Rosato; Sophie Wang; Linda Cui; Jay A Berzofsky; David E Kleiner; Dale B Bosco; Long-Jun Wu; Chunwei Walter Lai; Yaron Rotman; Changqing Xie; Firouzeh Korangy; Tim F Greten
Journal:  Cancer Cell       Date:  2022-09-01       Impact factor: 38.585

5.  Metformin treatment rescues CD8+ T-cell response to immune checkpoint inhibitor therapy in mice with NAFLD.

Authors:  Simon Wabitsch; Justin D McCallen; Olena Kamenyeva; Benjamin Ruf; John C McVey; Juraj Kabat; Juliane S Walz; Yaron Rotman; Kylynda C Bauer; Amanda J Craig; Marie Pouzolles; Ira Phadke; Vanessa Catania; Benjamin L Green; Claude Fu; Laurence P Diggs; Bernd Heinrich; Xin Wei Wang; Chi Ma; Tim F Greten
Journal:  J Hepatol       Date:  2022-04-01       Impact factor: 30.083

Review 6.  Understanding the cellular interactome of non-alcoholic fatty liver disease.

Authors:  Sebastian J Wallace; Frank Tacke; Robert F Schwabe; Neil C Henderson
Journal:  JHEP Rep       Date:  2022-06-15

Review 7.  Hepatic Stellate Cell-Immune Interactions in NASH.

Authors:  James K Carter; Scott L Friedman
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-09       Impact factor: 6.055

8.  Enrichment Methods for Murine Liver Non-Parenchymal Cells Differentially Affect Their Immunophenotype and Responsiveness towards Stimulation.

Authors:  Carolina Medina-Montano; Maximiliano Luis Cacicedo; Malin Svensson; Maria Jose Limeres; Yanira Zeyn; Jean Emiro Chaves-Giraldo; Nadine Röhrig; Stephan Grabbe; Stephan Gehring; Matthias Bros
Journal:  Int J Mol Sci       Date:  2022-06-11       Impact factor: 6.208

Review 9.  The immunological and metabolic landscape in primary and metastatic liver cancer.

Authors:  Xin Li; Pierluigi Ramadori; Dominik Pfister; Marco Seehawer; Lars Zender; Mathias Heikenwalder
Journal:  Nat Rev Cancer       Date:  2021-07-29       Impact factor: 60.716

Review 10.  Dendritic Cell-Mediated Regulation of Liver Ischemia-Reperfusion Injury and Liver Transplant Rejection.

Authors:  Ryosuke Nakano; Lillian M Tran; David A Geller; Camila Macedo; Diana M Metes; Angus W Thomson
Journal:  Front Immunol       Date:  2021-06-28       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.